RU2271830C1 - Method for vaccine prophylaxis of rubella in thule - Google Patents

Abstract

FIELD: medicine, immunology.

SUBSTANCE: vaccine Rudivax is administered to group of girls not younger than 13 years old leaving Thule regions not later than 55 days before departure. Similarly group of homing girls not younger than 13 years old are vaccinated not early than 90 days after coming in Thule regions from other climatic regions.

EFFECT: presence of protective titers of anti-rubella antibodies in vaccinated girls for 1 year after vaccination.

6 ex

Description

The invention relates to medicine and can be used for vaccination of rubella in the period of adaptation to the conditions of the Far North.

There is a method of vaccination against rubella vaccine Rudivax all girls aged 13 years old [Ministry of Health of the Russian Federation. The new calendar of vaccinations in Russia. Order No. 229. - M .: 06/27/2001].

The above method of vaccination is used throughout the Russian Federation, which includes regions with different climatic conditions, including the Far North. In the Far North there are a large number of residents who periodically travel to other regions. For residents of the Far North, who arrived from mid-latitudes, adaptation processes take a long time, sometimes throughout their lives. The disadvantage of this method is that in the Far North vaccinated girls over 13 years old, regardless of the length of time before leaving, or after arriving in the Far North from other regions. Changing the region of residence, even temporary, leads to disruption of the process of adaptation of the human body to the conditions of the Far North. It does not take into account the fact that in the body of those vaccinated in the Far North, the formation of immunity lasts longer than in mid-latitude conditions, where 21-30 days are enough. These factors reduce the effectiveness of vaccination.

In addition, the known method requires significant material and labor costs.

The objective of the present invention is to increase the effectiveness of the method of vaccination.

The essence of the invention lies in the fact that in the method of vaccination of rubella in the High North, which consists in the introduction of the Rudivax vaccine to girls no younger than 13 years old, according to the invention form a group leaving the Far North and vaccinate them no later than 55 days before departure, and form a group of returnees and vaccinate them no earlier than 90 days after arriving in the regions of the Far North from other climatic zones.

The pre-departure period of 55 days and the post-arrival period of 90 days ensures the creation of favorable conditions for the formation of adaptation processes that occur in the human body when changing latitudinal belts, and helps to increase the effectiveness of rubella vaccination in the Far North.

The method is as follows. When scheduling a vaccine against rubella among girls at least 13 years of age living in the Far North, data are collected on the timing of their likely departure to other climatic zones and return. Form a group of departing and a group of returnees subject to vaccination. Rudivax vaccine is administered to members of the departure group no later than 55 days before departure to other climatic zones. After returning to the Far North, members of the returning group are given the Rudivax vaccine no earlier than 90 days later.

Example 1. Levchenko I., 13 years old. Included in the group of travelers. Vaccinated with Rudivax vaccine 30 days prior to departure from the Far North region. 1 year after vaccination, anti-rubella antibodies were not detected (ΔOP <0.207) - seronegative.

Example 2. Oreshnikova N., 14 years old. Included in the group of travelers. Vaccinated with Rudivax vaccine 40 days before leaving the Far North region. 1 year after vaccination, anti-rubella antibodies were not detected (ΔOP <0.207) - seronegative.

Example 3. Mansurova S., 13 years old. Included in the group of travelers. Vaccinated with Rudivax vaccine 55 days before departure from the Far North regions. One year after vaccination, anti-rubella antibodies were detected in protective titers (ΔOP = 1.13).

Example 4. Sumaneeva S., 14 years old. Included in the returning group. Vaccinated with Rudivax vaccine 60 days after arrival in the Far North. 1 year after vaccination, anti-rubella antibodies were not detected (ΔOP <0.207) - seronegative.

Example 5. Shadrina O., 13 years old. Included in the returning group. Vaccinated with Rudivax vaccine 70 days after arrival in the Far North. 1 year after vaccination, anti-rubella antibodies were not detected (ΔOP <0.207) - seronegative.

Example 6. Vanderova L., 14 years old. Included in the returning group. Vaccinated with ADS-m toxoid 90 days after arrival in the Far North. One year after vaccination, anti-rubella antibodies were detected in protective titers (ΔOP = 0.83).

In total, in the conditions of the Far North, 673 people were vaccinated with the Rudivax vaccine according to the proposed method. The greatest effectiveness of vaccine prevention was obtained no later than 55 days before departure and no earlier than 90 days after arrival in the Far North.

Using the proposed method provides:

- improving the effectiveness of rubella vaccination;

- reduction of material and labor costs by reducing the season for vaccination and reducing the cost of operating helicopter transport and teams of doctors.

Claims (1)

The rubella vaccine prophylaxis method in the Far North, consisting in the introduction of the Rudivax vaccine to girls no younger than 13 years old, characterized in that they form a group of people leaving the Far North and vaccinate them no later than 55 days before departure, form a group of returnees and vaccinate them no earlier than 90 days after arriving in the regions of the Far North from other climatic zones.